Lattice Biologics Profit Margin

As of the most recent data (June 2021), LBLTF shows a profit margin of -59.23%. That compares with -87.27% in the prior-year period — up 32.1% year over year. That is below the sector sector average of 13.23%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LBLTF's profit margin is now -59.23% (was -87.27%) — a 32.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Lattice Biologics is outperforming or lagging.

The its sector sector average profit margin is about 13.23%. Lattice Biologics is at -59.23%, which is lower that average. That is roughly 547.8% below the sector mean. Use the comparison chart on this page to see how LBLTF stacks up against individual peers as well.

That compares with -87.27% in the prior-year period — up 32.1% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Lattice Biologics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Lattice Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -59.23%) with ownership activity and broader fundamentals.